Middle East & Africa Molecular Diagnostics Market (2025-2032)
The Middle East & Africa Molecular Diagnostics Market was valued at $0.77 billion in 2024. This market is expected to reach $1.16 billion by 2032, from an estimated $0.81 billion in 2025, at a CAGR of 5.4% during the forecast period 2025-2032. Middle East & Africa Molecular Diagnostics Market Size
- Published
- Feb 2024
- Pages
- 200
- Format
- PDF + Excel
- Report ID
- MRHC - 1041108
- Base year
- 2024
- 2024 · BASELINE
- $770.0M
- 2032
- $1.16B
- CAGR 2025–2032
- 5.4%
2024 baseline · 2025–2032 forecast at 5.4% CAGR · hover a bar for the value
Key highlights
The Reagents & Kits Segment is Expected to Account for the Largest Share of the Market in 2025
The Laboratory Tests Segment is Expected to Account for the Largest Share of the Market in 2025
The Polymerase Chain Reaction (PCR) Segment is Expected to Account for the Largest Share of the Market in 2025
The Infectious Disease Segment is Expected to Account for the Largest Share of the Market in 2025
The Hospitals & Clinics Segment is Expected to Account for the Largest Share of the Market in 2025
Saudi Arabia: Largest Market in the Middle East & Africa
Report summary
| Particulars | Details |
|---|---|
| Page No | ~200 |
| Format | |
| Forecast Period | 2025-2032 |
| Base Year | 2024 |
| CAGR | 5.4% |
| Market Size (Value) | $1.16 billion by 2032 |
| Segments Covered | By Offering · Kits & Reagents · Instruments · Software & Services · By Test Type · Laboratory Tests · Point-of-Care (POC) Tests · By Technology · Polymerase Chain Reaction (PCR) · In Situ Hybridization (ISH) · Isothermal Nucleic Acid Amplification Technology (INAAT) · Microarrays · Sequencing · Mass Spectrometry · Other Technologies · (Note: Other technologies primarily include electrophoresis, southern blotting, northern blotting, and ligase chain reaction (LCR)) · By Application · Infectious Diseases · Respiratory Diseases · Hepatitis · HIV · Chlamydia Trachomatis/Neisseria Gonorrhoeae · Human Papillomavirus (HPV) · Healthcare-Associated Infections (HAIs) · Other Infectious Diseases · (Note: Other infectious diseases primarily include meningococcal disease, norovirus (stomach flu), tropical diseases, hand, foot, and mouth disease (HFMD), and pertussis) · Oncology · Breast Cancer · Colorectal Cancer · Lung Cancer · Prostate Cancer · Lymphoma · Leukemia · Cervical Cancer · Other Cancer Types · (Note: Other cancer types include bladder cancer, melanoma, kidney cancer, stomach cancer, ovarian cancer, thyroid cancer, and chest cancer) · Genetic Testing · Neurological Diseases · Cardiovascular Diseases · Other Applications · (Note: Other applications primarily include pharmacogenomics, forensic testing, environmental studies, educational study purposes, human & microorganism genomic research studies, and food & beverages testing) · By End User · Hospitals & Clinics · Diagnostic Laboratories · Academic & Research Institutes · Other End Users · (Note: Other end users primarily include blood banks, ambulatory care centers, nursing homes, home care facilities, self-testing, the food & beverage industry, and forensic and environmental testing laboratories) |
| Countries Covered | Saudi Arabia, United Arab Emirates, Oman, Kuwait, Egypt, South Africa, and the Rest of the Middle East & Africa |
| Key Companies | AstraGene LLC (U.A.E.), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Becton, Dickinson and Company (U.S.), Illumina, Inc. (U.S.), AstraZeneca Gulf FZ LLC (Dubai), QIAGEN N.V. (Netherlands), Danaher Corporation (U.S.), Abbott Laboratories (U.S), Agilent Technologies, Inc. (U.S.) |
Report overview
Segments covered: offering, kits & reagent, instrument, software & service, test type, laboratory test, technology, microarray, sequencing, mass spectrometry, other technology, application, infectious disease, respiratory disease, hepatitis, hiv, chlamydia trachomatis/neisseria gonorrhoeae, other infectious disease, oncology, breast cancer, colorectal cancer, lung cancer, prostate cancer, lymphoma, leukemia, cervical cancer, other cancer type, genetic testing, neurological disease, cardiovascular disease, other application, end user, hospitals & clinic, diagnostic laboratory, academic & research institute, other end user.
Molecular diagnostics help identify specific genetic material within human, viral, and bacterial genomes. These tests are becoming increasingly prevalent across various fields, including infectious diseases, oncology, and clinical genetics. As advancements in molecular diagnostics persist, they will further enhance the accuracy and efficiency of diagnosis, ultimately becoming integral components of personalized patient interventions and therapeutic approaches.
The growth of the Middle East & Africa molecular diagnostics market is driven by factors such as the rising prevalence of communicable and non-communicable diseases, technological advancements in molecular diagnostics, increasing investments and funding aimed at enhancing healthcare systems in the Middle East & Africa, and the rising healthcare expenditure in the region. However, inconsistencies in medical device regulations across the Middle East & Africa and the high costs of molecular diagnostic tests restrain the market’s growth.
Emerging medical and wellness tourism in the UAE and a growing focus on companion diagnostics are expected to create market growth opportunities. However, the shortage of skilled professionals poses a significant challenge to the growth of this market.
Report infographic
Market dynamics
3 factors across 1 forceIn January 2022,
GC Labs (South Korea) proposed a “smart lab” concept that provides an automated test system to improve the speed and efficiency of tests. The increased demand for genetics and infectious diseases tests in the region has made GC Labs plan further expansion in the Middle East.
In December 2021,
AstraZeneca Gulf FZ LLC (UAE) partnered with G42 Healthcare (UAE) to boost the research and diagnostics in molecular diagnostics technology in the UAE. In June 2021, G42 Healthcare also signed a Memorandum of Understanding (MoU) with Seegene, Inc. (South Korea) to offer fully equipped mobile diagnostics and testing laboratories across the Middle East and North Africa (MENA) region. The partnership was aimed at providing the Seegene Mobile Station, a laboratory-on-wheels facility to provide optimized molecular diagnosis and tests across MENA, including the UAE, Algeria, Morocco, Tunisia, Libya, Egypt, Sudan, Palestine, Jordan, Syria, Iraq, Iran, Pakistan, Lebanon, Kuwait, Qatar, Oman, Saudi Arabia, Bahrain, and Yemen.
Funding and Investments to Improve Accessibility to Healthcare Services Driving Market’s Growth
Healthcare expenditure encompasses all financial investments necessary for healthcare systems to operate effectively and deliver high-quality care to patients. The increase in healthcare expenditure can facilitate regular health interventions, such as annual medical checkups and preventive screenings, which are likely to enhance the overall health status of a country. Despite the relatively low healthcare expenditure in the African region, various private and public organizations are actively investing in Africa to enhance basic healthcare infrastructure and combat diseases. For instance, in June 2022, the Bill & Melinda Gates Foundation (BMGF) announced a USD 140 million funding initiative over four years aimed at supporting new initiatives and research conducted by African institutions to combat malaria and neglected tropical diseases (NTDs). Similarly, in June 2020, New Frontier Capital Management (NCFM), a Japanese-owned investment firm, invested USD 300 million in the development of hospitals, medical infrastructure, medical systems, health tech, and health promotion in the Middle East & Africa region. Such investments are expected to drive the growth of the molecular diagnostics market in the years to come.
The rising healthcare expenditure indicates a growing emphasis on promoting health and preventing diseases, ultimately leading to an increased adoption of advanced medical technologies. This trend is accompanied by increased funding and initiatives for disease diagnosis and treatment, as well as the establishment of healthcare facilities and advanced infrastructure. These factors are increasing accessibility to advanced diagnostic methods for early diagnosis and treatment.
Table of contents
13 chapters · 103 sections · 200 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Offerings Studied in This Report | Reagents & Kits | — |
| By Test Types Studied in This Report | Laboratory Tests | — |
| By Technologies Studied in This Report | Polymerase Chain Reaction (PCR) | — |
| By Application | Infectious Disease | — |
| By End User | Hospitals & Clinics | — |
By Offerings Studied in This Report
- The reagents & kits segment is expected to account for the largest share of the market.
- Molecular diagnostic kits are widely used by healthcare professionals in hospitals, clinics, and diagnostic laboratories to diagnose and manage various communicable & non-communicable diseases.
- Recurrent use of assays & kits in the detection of various diseases through molecular diagnostics, the proliferation of new products in the market, and technological advancements in molecular techniques contribute to the large market share of this segment.
- Partnerships, collaborations, and agreements among the players and other industry stakeholders are also positively impacting the market.
- In April 2024, Thermo Fisher Scientific, Inc. (U.S.) partnered with ALPCO Diagnostics (Czech Republic) to introduce 37 CE-IVD molecular assays to the market.
- One such assay is the TaqPath Menu| GeneProof PCR Kit, which can be used on a wide range of qPCR instruments.
- This kit facilitates the detection of various genetic diseases and pathogens, including STDs, respiratory infections, and bloodborne infections.
- These assays enable laboratories to conduct tests more rapidly and reduce the need for frequent instrument changes, enhancing efficiency.
- The tests are slated to be launched in regions such as the Middle East, Africa, Latin America, Asia, and select parts of Europe throughout 2025.
By Test Types Studied in This Report
- The laboratory tests segment is expected to account for the largest share of the market.
- Laboratory tests have traditionally been conducted in hospitals and diagnostic centers.
- The laboratory testing approach for molecular diagnostics offers numerous advantages over other methods.
- It is characterized by higher accuracy and reliability compared to point-of-care testing, which contributes to its greater adoption in laboratory settings compared to PoC tests.
By Technologies Studied in This Report
- The polymerase chain reaction (PCR) segment is expected to account for the largest share of the molecular diagnostics market in the Middle East & Africa.
- PCR enables the rapid amplification of a specific segment of DNA, making it a crucial technology that aids in disease diagnosis.
- Due to its effectiveness in detecting low-number targets and its cost-effectiveness compared to other technologies like sequencing, there is significant demand for PCR tests, further bolstering the segment's largest share.
- For instance, in February 2024, Dubai, UAE, hosted the "Medlab Middle East 2024" exhibition and conference, a 4-day event showcasing the latest products and technologies in laboratory management and diagnostics, including PCR.
- Such exhibitions and conferences play a crucial role in increasing awareness of advanced technologies and instrumentation.
By Application
- The infectious disease segment is expected to account for the largest share of the molecular diagnostics market in the Middle East & Africa.
- The large market share of this segment can be attributed to the growing incidence of infectious diseases and increased funding for infectious disease diagnostic research activities.
- The availability of funding specifically allocated for infectious disease research contributes to the growth of this segment.
- For instance, in April 2021, the Jameel Fund for Infectious Disease Research and Innovation announced a research fund aimed at supporting collaborative research between King Abdulaziz University (KAU) in Saudi Arabia and Imperial College London in the U.K. Under this initiative, grants totaling USD 500,000 were provided, equally distributed between both universities to support research projects spanning three to six months in duration.
By End User
- The hospitals & clinics segment is expected to account for the largest share of the molecular diagnostics market in the Middle East & Africa.
- The large market share of this segment can be attributed to various initiatives aimed at enhancing healthcare infrastructure in the Middle East & Africa, increased hospitalizations due to various diseases, the growing geriatric population, and the high incidence of infectious diseases.
- For instance, in January 2024, the Sub-Saharan African region announced plans to invest nearly USD 11 billion in developing new hospitals to bolster the healthcare infrastructure of the region.
Geographic analysis
Middle East & Africa
Largest shareSaudi Arabia's significant market share can be attributed to factors such as the robust healthcare infrastructure in the country, the increasing prevalence of chronic and infectious diseases, and the rising spending on healthcare. According to the International Trade Administration (ITA), under the Vision 2032 initiative, the Saudi Arabian government plans to invest over USD 65 million in the development of healthcare infrastructure and to reorganize and privatize health services. In 2024, Saudi Arabia allocated nearly USD 50.4 billion for healthcare and social development, representing approximately 16.96% of the total budget for that year. This high healthcare spending underscores the country's strong focus on healthcare-related activities and services, including government procurements of pharmaceuticals, medical equipment, and supplies for the benefit of all public healthcare facilities. Saudi Arabia: Largest Market in the Middle East & Africa
Competitive landscape
The key players profiled in the Middle East & Africa molecular diagnostics market report are AstraGene LLC (U.A.E.), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Becton, Dickinson and Company (U.S.), Illumina, Inc. (U.S.), AstraZeneca Gulf FZ LLC (Dubai), QIAGEN N.V. (Netherlands), Danaher Corporation (U.S.), Abbott Laboratories (U.S), and Agilent Technologies, Inc. (U.S.).
The report includes a competitive landscape based on an extensive assessment of the market based on offering, test type, application, technology, and end user. The report also provides insights into the presence of major market players and the key growth strategies adopted by them over the past three to four years.
- AstraGene LLC (U.A.E.)
- F. Hoffmann-La Roche Ltd. · Switzerland
- Thermo Fisher Scientific Inc. (U.S.)
- Becton
- Dickinson and Company (U.S.)
- Illumina, Inc. (U.S.)
- AstraZeneca Gulf FZ LLC · Dubai
- QIAGEN N.V. · Netherlands
- Danaher Corporation (U.S.)
- Abbott Laboratories (U.S)
- Agilent Technologies, Inc. (U.S.)
Frequently asked questions
This market study covers the market sizes & forecasts of the molecular diagnostics market in the Middle East & Africa based on offering, test type, technology, application, end user, and geography. This market study also provides the value analysis of various segments and subsegments of the Middle East & Africa molecular diagnostics market at country levels.
Cite this report
Meticulous Research. (2024). Middle East & Africa Molecular Diagnostics Market - Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MRHC - 1041108). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/middle-east-and-africa-molecular-diagnostics-market-5791